Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.47), $0.08 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• Agilent Technologies (A) Tops Q3 EPS by 13c, Beats on Revenue; Offers FY EPS Guidance
• Williams-Sonoma (WSM) Tops Q2 EPS by 4c